StageZero Life Sciences Ltd. (TSXV: SZLS.H)
Health Care · Biotechnology · CA
CA$—
— today · — 1Y
StageZero Life Sciences Ltd. (TSXV: SZLS.H) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.64M and employs 40 people.
trading between 0.04 and 0.10.
Tweenvest scores StageZero Life Sciences Ltd. across four factors: quality 7/100, growth 0/100. Its strongest factor is quality.
SZLS.H price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.64M
- Revenue (TTM)
- $2.88M
- P/E
- —
- EPS
- -0.12
- Dividend yield
- —
- Beta (5Y)
- 0.34
- 52-week high
- CA$0.10
- 52-week low
- CA$0.04
- Avg volume (3M)
- —
- Shares outstanding
- 123.55M
- Employees
- 40
- Next earnings
- —
About StageZero Life Sciences Ltd.
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
- ISIN
- CA8525403017
- Listed since
- Jan 7, 2004
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.